26
|
Berkani N, Joly P, Golinski ML, Colliou N, Lim A, Larbi A, Riou G, Caillot F, Bernard P, Bedane C, Delaporte E, Chaby G, Dompmartin A, Hertl M, Calbo S, Musette P. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep 2019; 9:3525. [PMID: 30837635 PMCID: PMC6401188 DOI: 10.1038/s41598-019-40203-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 02/04/2019] [Indexed: 11/08/2022] Open
Abstract
Bullous Pemphigoid is the most common auto-immune bullous skin disease. It is characterized by the production of auto-antibodies directed against 2 proteins of the hemi-desmosome (BP180 and BP230). We assessed the efficacy and mechanisms of action of rituximab, an anti-CD20 monoclonal antibody, in 17 patients with severe and relapsing type of bullous pemphigoid. The phenotype, cytokine gene expression, and rearrangement of BP180-specific B-cell receptor genes were performed over 2 years following treatment. At the end of the study, 5 patients had died, 3 had withdrawn from the study, and 9 patients were in complete remission. The one- and two-year relapse rates were 44.1% (95% Confidence Interval (CI): 21.0-76.0%) and 66.5%, (95% CI: 38.4-91.4%), respectively. Phenotypic analyses confirmed dramatic B-cell depletion, which lasted for 9 to 12 months. The ELISA values of serum anti-BP180 antibodies and the frequency of BP180-specific circulating B cells decreased dramatically following treatment, which paralleled the improvement of skin lesions. During B-cell reconstitution, a polyclonal IgM repertoire appeared and a shift in the rearrangement of the B-cell receptor genes of BP180-specific circulating B cells was observed. Concurrently, we observed a decrease of IL-15, IL-6 and TNFα expressing BP180-specific B cells, and the emergence of IL-10 and IL-1RA-expressing BP180-specific IgM+ B cells in patients in complete remission off therapy, suggesting the functional plasticity of BP180-specific auto-immune B cells after rituximab treatment.
Collapse
|
27
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D'incan M, Verneuil L, Litrowski N, Joly P. Incidence and Mortality of Pemphigus in France. J Invest Dermatol 2019; 139:469-473. [DOI: 10.1016/j.jid.2018.07.042] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 07/13/2018] [Accepted: 07/27/2018] [Indexed: 10/28/2022]
|
28
|
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019; 139:31-37. [DOI: 10.1016/j.jid.2018.04.042] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 11/29/2022]
|
29
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Delaumenie S, Assikar S, Prud’homme R, Matei I, Couture M, Souyri N, Couraud A, Bedane C. Efficacité et tolérance du méthotrexate dans la pemphigoïde bulleuse en Limousin. Étude rétrospective de 52 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Pittoni J, Bedane C, Diabate A, Couture M, Prud’homme R, Matei I, Assikar S, Audevard D. Efficacité d’un anti-IL6 dans deux cas de pemphigoïde bulleuse sévère. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Douard P, Prud’Homme R, Assikar S, Matei I, Bourgaux M, Jaccard A, Bedane C. Association myélome et dermatose à IgA intra-épidermique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Marcaillou M, Bourgaux M, Prud’homme R, Matei I, Assikar S, Bedane C. Efficacité de l’imatinib (Glivec®) sur deux mélanomes muqueux métastatiques mutés KIT. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Nespoulous L, Dalmay F, Bedane C, Assikar S. Étude des facteurs pronostiques de la pemphigoïde bulleuse chez 329 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Masmoudi W, Hebert V, Quéreux G, Bedane C, Prost-Squarcioni C, Debarbieux S, Oro S, Chaby G, D’incan M, Litrowski N, Boulard C, Roussel A, Kottler D, Abasq C, Richard MA, Duvert-Lehembre S, Gottlieb J, Plantin P, Joly P. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Mortalité du pemphigus et facteurs pronostiques, incluant les traitements initialement proposés. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Naqi A, Bedane C, Souyri N, Diabaté A. Photosensibilité persistante au verteporfin. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Bedane C, Misery L, Martin L, Aubron-Olivier C, Chalmers R. Évaluation de l’efficacité du secukinumab à l’aide de l’indice simplifié du Psoriasis : résultat d’une étude clinique prospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Douard P, Assikar S, Matei I, Prud’homme R, Audevar D, Bedane C. Pemphigus vulgaire et réactivation virale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. J Invest Dermatol 2017; 138:58-67. [PMID: 28843487 DOI: 10.1016/j.jid.2017.07.839] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 06/18/2017] [Accepted: 07/14/2017] [Indexed: 01/30/2023]
Abstract
Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array, and immunostaining of downstream KIT effectors were performed during treatment. Twenty-five patients were included and received 400 mg oral nilotinib twice daily. At 6 months, nilotinib induced tumor response in four patients. The best overall response rate was 20% and the disease control rate was 56%, limited to patients harboring exon 11 or 13 mutations. Four patients exhibited durable response, including three persisting (3.6 and 2.8 years for two patients with stage IIIC and 2.5 years for one with IVM1b melanoma). A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response. In the KIT-mutated melanoma cell line M230, nilotinib reduced STAT3 signaling and STAT inhibitors were as efficient as KIT inhibitors in reducing cell proliferation. Our study evidences a significant association between STAT3 inhibition and response to nilotinib, and provides a rationale for future research assessing STAT inhibitors in KIT-mutated melanoma.
Collapse
|
41
|
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389:2031-2040. [PMID: 28342637 DOI: 10.1016/s0140-6736(17)30070-3] [Citation(s) in RCA: 347] [Impact Index Per Article: 49.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/07/2016] [Accepted: 11/16/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with corticosteroid treatment alone, while decreasing treatment side-effects of corticosteroids. METHODS We did a prospective, multicentre, parallel-group, open-label, randomised trial in 25 dermatology hospital departments in France (Ritux 3). Eligible participants were patients with newly diagnosed pemphigus aged 18-80 years being treated for the first time (not at the time of a relapse). We randomly assigned participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24, then an additional visit at month 36). Treatment was assigned through central computer-generated randomisation, with stratification according to disease-severity (severe or moderate, based on Harman's criteria). The primary endpoint was the proportion of patients who achieved complete remission off-therapy at month 24 (intention-to-treat analysis). This study is registered with ClinicalTrials.gov, number NCT00784589. FINDINGS Between May 10, 2010, and Dec 7, 2012, we enrolled 91 patients and randomly assigned 90 to treatment (90 were analysed; 1 patient withdrew consent before the random assignment). At month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (absolute difference 55 percentage points, 95% CI 38·4-71·7; p<0·0001. This difference corresponded to a relative risk of success of 2·61 (95% CI 1·71-3·99, p<0·0001), corresponding to 1·82 patients (95% CI 1·39-2·60) who would need to be treated with rituximab plus prednisone (rather than prednisone alone) for one additional success. No patient died during the study. More severe adverse events of grade 3-4 were reported in the prednisone-alone group (53 events in 29 patients; mean 1·20 [SD 1·25]) than in the rituximab plus prednisone group (27 events in 16 patients; mean 0·59 [1·15]; p=0·0021). The most common of these events in both groups were diabetes and endocrine disorder (11 [21%] with prednisone alone vs six [22%] with rituximab plus prednisone), myopathy (ten [19%] vs three [11%]), and bone disorders (five [9%] vs five [19%]). INTERPRETATION Data from our trial suggest that first-line use of rituximab plus short-term prednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events. FUNDING French Ministry of Health, French Society of Dermatology, Roche.
Collapse
|
42
|
Delaumenie S, Assikar S, Matei I, Souyri N, Audevard D, Bedane C. Psoriasis et pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Jelti L, Le Bourhis-Zaimi M, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Incidence et mortalité du pemphigus en France. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Woillard JB, Maffioletti PF, Assikar S, Monchaud C, Marquet P, Couraud A, Matei I, Bedane C. Intérêt du suivi thérapeutique pharmacologique de l’acide mycophénolique chez des patients traités pour pemphigoïde cicatricielle. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Couture M, Laumonier J, Audevard D, Assikar S, Bordes S, Closs B, Bedane C. L’IL6 est significativement augmentée dans les formes sévères de pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
46
|
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2016; 31:e254-e257. [PMID: 27739129 DOI: 10.1111/jdv.14011] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Rigot E, Cypierre A, Liozon E, Bézananary H, Gondran G, Ly K, Fauchais A, Bedane C, Palat S. Prise en charge de la douleur engendrée par les ulcérations digitales dans la sclérodermie : résultats d’une enquête de pratique. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
|
49
|
Houx L, Hachulla E, Kone-Paut I, Quartier P, Touitou I, Guennoc X, Grateau G, Hamidou M, Neven B, Berthelot JM, Lequerré T, Pillet P, Lemelle I, Fischbach M, Duquesne A, Le Blay P, Le Jeunne C, Stirnemann J, Bonnet C, Gaillard D, Alix L, Touraine R, Garcier F, Bedane C, Jurquet AL, Duffau P, Smail A, Frances C, Grall-Lerosey M, Cathebras P, Tran TA, Morell-Dubois S, Pagnier A, Richez C, Cuisset L, Devauchelle-Pensec V. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study. Arthritis Rheumatol 2016; 67:3027-36. [PMID: 26245507 DOI: 10.1002/art.39292] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 07/16/2015] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To determine the type and frequency of musculoskeletal symptoms at onset and during followup of cryopyrin-associated periodic syndromes (CAPS). METHODS We retrospectively recorded the articular and muscular symptoms of patients with CAPS followed up in French hospitals. Data were presented as frequencies or the median (range), and patient groups were compared using chi-square test, Fisher's exact test, and Mann-Whitney test. RESULTS The study included 133 patients (33 children), 20 with familial cold autoinflammatory syndrome, 88 with Muckle-Wells syndrome, 22 with chronic infantile neurologic, cutaneous, articular syndrome, and 3 with unclassified CAPS. The median age was 35 years (range 0-78 years) at the time of the study, 1 year (range 0-41 years) at symptom onset, and 23 years (range 0-58 years) at diagnosis. The disease was sporadic in 17% of the patients. Cutaneous symptoms predominated at onset (77%), followed by articular symptoms (30%). The p.Thr348Met and p.Arg260Trp NLRP3 mutations were significantly associated with the presence and absence of articular symptoms at onset, respectively. During followup, 86% of the patients had musculoskeletal symptoms, 88% had arthralgia, and 58% had arthritis, but only 9% had joint destruction. Tendinopathies occurred in 21.5% of the patients, tender points in 16.5%, and myalgia in 33%. Only 3 patients had typical knee deformities. Radiographs were rarely obtained. Except for bone deformities, osteoarticular symptoms occurred at similar frequencies in the different CAPS phenotypes. CONCLUSION Joint manifestations were frequent in all CAPS phenotypes. Bone deformities were rare. Musculoskeletal manifestations varied within given families but tended to worsen over time.
Collapse
|
50
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|